Pharmacokinetics of daily daptomycin in critically ill patients undergoing continuous renal replacement therapy

Chemotherapy

Volumn 59, Issue 2, 2013, Pages 143-151

  Corti, Natascia ^a   Rudiger, Alain ^b   Chiesa, Alessandro ^a   Marti, Isabelle ^a   Jetter, Alexander ^a   Rentsch, Katharina ^c   Müller, Daniel ^c   Béchir, Markus ^a   Maggiorini, Marco ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^c UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

Antibiotics; Dosing; Gram positive infection; Intensive care; Renal failure; Renal replacement therapy

Indexed keywords

CREATINE KINASE; DAPTOMYCIN; SERUM ALBUMIN;

AREA UNDER THE CURVE; ARTICLE; CHRONIC KIDNEY FAILURE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTINUOUS RENAL REPLACEMENT THERAPY; CRITICALLY ILL PATIENT; DRUG BLOOD LEVEL; DRUG CLEARANCE; FEMALE; GRAM POSITIVE INFECTION; HUMAN; MALE; MAXIMUM PLASMA CONCENTRATION; PRIORITY JOURNAL; SIDE EFFECT; ADULT; AGED; ALBUMIN BLOOD LEVEL; BIOEQUIVALENCE; DRUG ACCUMULATION; DRUG SAFETY; HYPERTRANSAMINASEMIA; MIDDLE AGED; MINIMUM PLASMA CONCENTRATION; PLASMA CONCENTRATION-TIME CURVE; PROSPECTIVE STUDY; STEADY STATE; TREATMENT DURATION; VERY ELDERLY;

AGED; AREA UNDER CURVE; CRITICAL ILLNESS; DAPTOMYCIN; DRUG ADMINISTRATION SCHEDULE; FEMALE; HALF-LIFE; HUMANS; MALE; MIDDLE AGED; RENAL REPLACEMENT THERAPY; ROC CURVE;

EID: 84886413396     PISSN: 00093157     EISSN: 14219794     Source Type: Journal    
DOI: 10.1159/000353400     Document Type: Article

References (24)

1. Hair PI, Keam SJ: Daptomycin: a review of its use in the management of complicated skin and soft-tissue infections and Staphylococcus aureus bacteraemia. Drugs 2007; 67: 1483-1512. (Pubitemid 47028521)
2. Woodworth JR, Nyhart EH Jr, Brier GL, Wolny JD, Black HR: Single-dose pharmaco-kinetics and antibacterial activity of daptomy-cin, a new lipopeptide antibiotic, in healthy volunteers. Antimicrob Agents Chemother 1992; 36: 318-325
3. ®: Label information FDA, 2011. http://www.accessdata.fda.gov/drugsatfda- docs/label/2011/021572s038lbl.pdf.
4. Matzke GR, Aronoff GR, Atkinson AJ Jr, Bennett WM, Decker BS, Eckardt KU, Golper T, Grabe DW, Kasiske B, Keller F, Kielstein JT, Mehta R, Mueller BA, Pasko DA, Schaefer F, Sica DA, Inker LA, Umans JG, Murray P: Drug dosing consideration in patients with acute and chronic kidney disease-a clinical update from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 2011; 80: 1122-1137.
5. Khadzhynov D, Slowinski T, Lieker I, Spies C, Puhlmann B, Konig T, Uhrig A, Eggers K, Neumayer HH, Traunmuller F, Joukhadar C, Peters H: Plasma pharmacokinetics of dapto-mycin in critically ill patients with renal failure and undergoing CVVHD. Int J Clin Pharmacol Ther 2011; 49: 656-665.
6. Wenisch JM, Meyer B, Fuhrmann V, Saria K, Zuba C, Dittrich P, Thalhammer F: Multiple-dose pharmacokinetics of daptomycin during continuous venovenous haemodiafiltration. J Antimicrob Chemother 2012; 67: 977-983.
7. Churchwell MD, Pasko DA, Mueller BA: Daptomycin clearance during modeled continuous renal replacement therapy. Blood Pu-rif 2006; 24: 548-554. (Pubitemid 46030098)
8. Preiswerk B, Rudiger A, Fehr J, Corti N: Experience with daptomycin daily dosing in ICU patients undergoing continuous renal replacement therapy. Infection 2013; 41: 553-557.
9. Benvenuto M, Benziger DP, Yankelev S, Vi-gliani G: Pharmacokinetics and tolerability of daptomycin at doses up to 12 milligrams per kilogram of body weight once daily in healthy volunteers. Antimicrob Agents Chemother 2006; 50: 3245-3249. (Pubitemid 44527494)
10. Dvorchik BH, Brazier D, DeBruin MF, Arbeit RD: Daptomycin pharmacokinetics and safety following administration of escalating doses once daily to healthy subjects. Antimicrob Agents Chemother 2003; 47: 1318-1323. (Pubitemid 36368592)
11. Safdar N, Andes D, Craig WA: In vivo pharmacodynamic activity of daptomycin. Antimicrob Agents Chemother 2004; 48: 63-68. (Pubitemid 38040177)
12. Hanberger H, Nilsson LE, Maller R, Isaksson B: Pharmacodynamics of daptomycin and vancomycin on Enterococcus faecalis and Staphylococcus aureus demonstrated by studies of initial killing and postantibiotic effect and influence of Ca2+ and albumin on these drugs. Antimicrob Agents Chemother 1991; 35: 1710-1716.
13. Daptomycin: rationale for the EUCAST clinical breakpoints, version 1.0. http://www.eu-cast.org/fileadmin/src/media/PDFs/EU-CAST-files/ Rationale-documents/Daptomycinrationale1.0.pdf (accessed April 10, 2013).
14. Bubalo JS, Munar MY, Cherala G, Hayes-Lat-tin B, Maziarz R: Daptomycin pharmacoki-netics in adult oncology patients with neutro-penic fever. Antimicrob Agents Chemother 2009; 53: 428-434.
15. Mohr JF 3rd, Ostrosky-Zeichner L, Wainright DJ, Parks DH, Hollenbeck TC, Ericsson CD: Pharmacokinetic evaluation of single-dose intravenous daptomycin in patients with thermal burn injury. Antimicrob Agents Che-mother 2008; 52: 1891-1893. (Pubitemid 351614698)
16. Bouman CS, van Kan HJ, Koopmans RP, Ko-revaar JC, Schultz MJ, Vroom MB: Discrepancies between observed and predicted continuous venovenous hemofiltration removal of antimicrobial agents in critically ill patients and the effects on dosing. Intensive Care Med 2006; 32: 2013-2019. (Pubitemid 44833115)
17. Clark WR, Turk JE, Kraus MA, Gao D: Dose determinants in continuous renal replacement therapy. Artif Organs 2003; 27: 815-820. (Pubitemid 37108622)
18. Vilay AM, Grio M, Depestel DD, Sowinski KM, Gao L, Heung M, Salama NN, Mueller BA: Daptomycin pharmacokinetics in critically ill patients receiving continuous venove-nous hemodialysis. Crit Care Med 2011; 39: 19-25.
19. Garrison MW, Rotschafer JC, Crossley KB: Suboptimal effect of daptomycin in the treatment of bacteremias. South Med J 1989; 82: 1414-1415. (Pubitemid 20008660)
20. Cha R, Grucz RG Jr, Rybak MJ: Daptomycin dose-effect relationship against resistant gram-positive organisms. Antimicrob Agents Chemother 2003; 47: 1598-1603. (Pubitemid 36548543)
21. Bowker KE, Noel AR, MacGowan AP: Comparative antibacterial effects of daptomycin, vancomycin and teicoplanin studied in an in vitro pharmacokinetic model of infection. J Antimicrob Chemother 2009; 64: 1044-1051.
22. Kielstein JT, Eugbers C, Bode-Boeger SM, Martens-Lobenhoffer J, Haller H, Joukhadar C, Traunmuller F, Knitsch W, Hafer C, Burk-hardt O: Dosing of daptomycin in intensive care unit patients with acute kidney injury undergoing extended dialysis-a pharmacoki-netic study. Nephrol Dial Transplant 2010; 25: 1537-1541.
23. Falcone M, Russo A, Cassetta MI, Lappa A, Tritapepe L, Fallani S, Vullo V, Venditti M, Novelli A: Daptomycin serum levels in critical patients undergoing continuous renal replacement. J Chemother 2012; 24: 253-256.
24. Rudiger A, Rentsch K, Maggiorini M, Corti N: Daptomycin pharmacokinetics in critically ill patients undergoing continuous renal replacement therapy. Crit Care Med 2011; 39: 1243-1244, author reply 1244-1245.